Business Description
Actuate Therapeutics Inc
NAICS : 541715
SIC : 2836
ISIN : US0050831009
Total Employee Number:
12Description
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.43 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 7.6 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | 8.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -7.72 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.69 | |||||
9-Day RSI | 26.58 | |||||
14-Day RSI | 30.34 | |||||
3-1 Month Momentum % | -24.19 | |||||
6-1 Month Momentum % | -68.82 | |||||
12-1 Month Momentum % | -72.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.8 | |||||
Quick Ratio | 1.8 | |||||
Cash Ratio | 1.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.7 | |||||
Shareholder Yield % | -67.85 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -722.59 | |||||
ROA % | -206.63 | |||||
ROIC % | -1675.49 | |||||
3-Year ROIIC % | -269.49 | |||||
ROCE % | -634.47 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.44 | |||||
Price-to-Tangible-Book | 9.44 | |||||
EV-to-EBIT | -1.98 | |||||
EV-to-EBITDA | -1.98 | |||||
EV-to-FCF | -2.18 | |||||
| Price-to-Net-Current-Asset-Value | 10.79 | |||||
| Price-to-Net-Cash | 11.62 | |||||
Earnings Yield (Greenblatt) % | -50.51 | |||||
FCF Yield % | -54.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ACTU
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Actuate Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.97 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 65.52 | ||
| 14-Day RSI | 30.34 | ||
| 14-Day ATR ($) | 0.23932 | ||
| 20-Day SMA ($) | 1.8705 | ||
| 12-1 Month Momentum % | -72.11 | ||
| 52-Week Range ($) | 1.4 - 9.22 | ||
| Shares Outstanding (Mil) | 23.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Actuate Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Actuate Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 40 days | ||
| General meeting for 2026 | 2026-05-21 11:00 | 2.51 (+5.02%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 2.97 (+2.77%) | ||
| Annual report for 2025 | 2026-03-26 | 2.32 (+1.75%) | ||
| Citizens Life Sciences Conference | 2026-03-10 08:25 | 2.95 (+1.90%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-26 09:20 | 4.06 (-2.87%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 6.30 (+4.91%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 8.53 (-1.04%) | ||
| General meeting for 2025 | 2025-05-22 10:30 | 10.98 (+4.37%) |
Show
Entries
Actuate Therapeutics Inc Frequently Asked Questions
What is Actuate Therapeutics Inc(ACTU)'s stock price today?
The current price of ACTU is $1.51. The 52 week high of ACTU is $9.22 and 52 week low is $1.40.
When is next earnings date of Actuate Therapeutics Inc(ACTU)?
The next earnings date of Actuate Therapeutics Inc(ACTU) is 2026-08-14 Est..
Does Actuate Therapeutics Inc(ACTU) pay dividends? If so, how much?
Actuate Therapeutics Inc(ACTU) does not pay dividend.
Guru Commentaries on NAS:ACTU
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers | 2026-03-24 |
Articles on Actuate Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers